Cargando…
Phase I study to evaluate the maximum tolerated dose of the combination of SH003 and docetaxel in patients with solid cancer: A study protocol
INTRODUCTION: Cancer is the second leading cause of death, and the burden of cancer continues to grow globally. Research on the efficacy of combined administration of herbal medicine and anticancer drugs is also increasing. SH003 is a new herbal medicine composed of Astragalus membranaceus, Angelica...
Autores principales: | Cheon, Chunhoo, Ko, Seong-Gyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505292/ https://www.ncbi.nlm.nih.gov/pubmed/32957363 http://dx.doi.org/10.1097/MD.0000000000022228 |
Ejemplares similares
-
A Phase I Study to Evaluate the Safety of the Herbal Medicine SH003
in Patients With Solid Cancer
por: Cheon, Chunhoo, et al.
Publicado: (2020) -
Single-arm, open-label, dose-escalation phase I study to evaluate the safety of a herbal medicine SH003 in patients with solid cancer: a study protocol
por: Cheon, Chunhoo, et al.
Publicado: (2018) -
SH003 activates autophagic cell death by activating ATF4 and inhibiting G9a under hypoxia in gastric cancer cells
por: Kim, Tae Woo, et al.
Publicado: (2020) -
State of the Art and Future Implications of SH003: Acting as a Therapeutic Anticancer Agent
por: Lee, Kangwook, et al.
Publicado: (2022) -
Synergistic effects of herbal medicines and anticancer drugs: A protocol for systematic review and meta-analysis
por: Cheon, Chunhoo
Publicado: (2021)